{"filings":[{"id":778877,"accession_number":"0001213900-26-063530","cik":1851484,"company_name":"CITIUS ONCOLOGY, INC.","ticker":"CTOR","form_type":"8-K","filed_at":"2026-06-01T20:30:18+00:00","items":["8.01","9.01"],"status":"ready","headline":"Citius Oncology reports Phase 1 combo data for LYMPHIR in gynecologic cancers; 24% ORR, 33% in endometrial cancer","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["24% ORR (5 partial responses) among 21 efficacy-evaluable patients with recurrent/refractory gynecologic malignancies.","33% ORR in endometrial cancer patients previously treated with checkpoint inhibitors; one response >3 years.","Median PFS of 20.5 months among 10 patients achieving clinical benefit (48% of evaluable patients).","Safety manageable: only 1 reversible Grade 3 capillary leak syndrome at highest dose; no new safety signals.","Phase 2 expansion study planned to further evaluate combination in gynecologic cancers including less heavily pre-treated patients."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":79963831.34210822,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":472036,"accession_number":"0001213900-26-057883","cik":1851484,"company_name":"CITIUS ONCOLOGY, INC.","ticker":"CTOR","form_type":"8-K","filed_at":"2026-05-15T20:44:23+00:00","items":["2.02","9.01"],"status":"ready","headline":"Citius Oncology reports Q2 FY2026 net loss $26.6M; LYMPHIR revenue $1.7M, launch progressing","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net product revenues $1.7M in Q2 ($5.6M H1) vs $0 prior year; gross margin 80%.","Net loss $26.6M vs $7.7M prior year, driven by $19.7M one-time CMO contract cancellation.","Cash $2.6M at March 31; subsequent $11.5M warrant exercise and $10M debt tranche from Avenue Capital ($25M facility).","83% of target accounts on formulary or in review; near 100% payer coverage; initial European shipment.","Hired Jefferies as exclusive financial advisor to evaluate strategic alternatives; combined cash runway through Nov 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.34,"consensus_revenue_estimate":null,"consensus_revenue_actual":5611409.0,"consensus_period":"2026-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":79963831.34210822,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":96228,"accession_number":"0001213900-26-052552","cik":1851484,"company_name":"CITIUS ONCOLOGY, INC.","ticker":"CTOR","form_type":"8-K","filed_at":"2026-05-06T23:59:59+00:00","items":["1.01","2.03","3.02","8.01","9.01"],"status":"ready","headline":"Citius Oncology secures up to $36.5M in debt and warrant exercise proceeds","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Warrant inducement yields ~$11.5M gross from exercise of 12.8M shares at $0.90; new warrants for 25.6M shares at $0.90.","Avenue Capital Group provides up to $25M senior secured credit facility; $10M initial tranche funded at close.","Avenue also receives warrants to buy up to 11.1M shares at $0.90 exercisable after stockholder approval.","Parent debt subordinated to new loan; promissory note amended to align with 91-day post-Senior Debt maturity."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":79963831.34210822,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":96227,"accession_number":"0001213900-26-049347","cik":1851484,"company_name":"CITIUS ONCOLOGY, INC.","ticker":"CTOR","form_type":"8-K","filed_at":"2026-04-29T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Citius Oncology ships first international LYMPHIR order to Europe via NPPs","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Initial shipment of LYMPHIR (denileukin diftitox-cxdl) to Europe through regional distribution partner.","Access via Named Patient Programs (NPPs) in local countries; no EMA marketing authorization.","LYMPHIR FDA-approved Aug 2024 for relapsed/refractory CTCL; US commercial launch in Dec 2025.","Company continues US launch with progress on formulary access, payer coverage, and physician engagement.","CEO Leonard Mazur cites commitment to expanding patient access beyond the US."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":79963831.34210822,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":96226,"accession_number":"0001213900-26-048629","cik":1851484,"company_name":"CITIUS ONCOLOGY, INC.","ticker":"CTOR","form_type":"8-K","filed_at":"2026-04-28T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Citius Oncology receives Nasdaq deficiency notice for falling below $1.00 bid price","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq notified Citius Oncology on April 22, 2026 that bid price closed below $1.00 for 30 consecutive business days.","Company has 180 days, until October 19, 2026, to regain compliance by closing at $1.00+ for 10 consecutive days.","If not compliant, may get additional 180 days if meet other standards and intend to cure via reverse stock split.","Company is evaluating options; stock continues trading under symbol CTOR."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":79963831.34210822,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":109942,"accession_number":"0001213900-26-037501","cik":1851484,"company_name":"CITIUS ONCOLOGY, INC.","ticker":"CTOR","form_type":"8-K","filed_at":"2026-03-31T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Citius Oncology reports early LYMPHIR launch traction; 83% of target accounts in formulary review","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["83% of target accounts have added or are actively progressing LYMPHIR through formulary review.","Market access covering ~80% of covered lives via ~135 health plans; no reimbursement denials reported.","Initial accounts placing repeat orders; sequential growth in orders since launch.","Investigator-led studies: LYMPHIR prior to CAR-T in DLBCL (U Minnesota) and combo with pembrolizumab in solid tumors (UPMC).","Field team onboarding underway; international expansion with distribution agreements in Europe/Middle East."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":79963831.34210822,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":109941,"accession_number":"0001213900-26-025464","cik":1851484,"company_name":"CITIUS ONCOLOGY, INC.","ticker":"CTOR","form_type":"8-K","filed_at":"2026-03-10T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Citius Oncology reports positive Phase 1 topline data for LYMPHIR + pembrolizumab in gynecologic cancers","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["24% objective response rate (ORR) and 48% clinical benefit rate (CBR) among 21 evaluable patients.","No unexpected safety signals or serious immune-related adverse events observed in 25 evaluable patients.","Investigator-initiated trial by University of Pittsburgh; full results expected at upcoming international cancer conference.","Study evaluated LYMPHIR (denileukin diftitox-cxdl) + pembrolizumab in relapsed/refractory ovarian and endometrial cancers."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":79963831.34210822,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":109940,"accession_number":"0001213900-26-023440","cik":1851484,"company_name":"CITIUS ONCOLOGY, INC.","ticker":"CTOR","form_type":"8-K","filed_at":"2026-03-04T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Citius Oncology reports positive Phase 1 data for LYMPHIR prior to CAR-T in DLBCL","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Overall response rate 86% (57% complete response, 29% partial response) at one month in 14 patients.","One-year progression-free survival 77% (95% CI 43-92%); overall survival 84% (95% CI 49-96%).","LYMPHIR well-tolerated with no dose-limiting toxicities; no Grade ≥3 LYMPHIR-related immune AEs.","Single LYMPHIR dose depleted circulating Tregs (median reduction 24 Tregs/µL); supports larger trial.","Study enrolled high-risk relapsed/refractory DLBCL patients; all proceeded to CAR-T infusion."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":79963831.34210822,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":109939,"accession_number":"0001213900-26-015894","cik":1851484,"company_name":"CITIUS ONCOLOGY, INC.","ticker":"CTOR","form_type":"8-K","filed_at":"2026-02-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Citius Oncology reports first revenue of $3.9M from LYMPHIR launch; net loss narrows to $5.5M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue of $3.9M for Q1 FY2026 ended Dec 31, 2025, first reported sales following December 2025 commercial launch of LYMPHIR.","Net loss of $5.5M ($0.06 per share) improved from $6.7M loss ($0.09) in prior-year period.","Cash and equivalents $7.3M as of Dec 31, 2025; raised net proceeds of ~$15.1M via December 2025 registered offering.","LYMPHIR (denileukin diftitox-cxdl) launched for relapsed/refractory Stage I-III cutaneous T-cell lymphoma; patient initiations underway at leading U.S. cancer centers.","AI-enabled commercial platform deployed; international access advanced through regional distribution partners in Europe and Middle East."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.06,"consensus_revenue_estimate":null,"consensus_revenue_actual":3944111.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":79963831.34210822,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":126517,"accession_number":"0001213900-25-125418","cik":1851484,"company_name":"CITIUS ONCOLOGY, INC.","ticker":"CTOR","form_type":"8-K","filed_at":"2025-12-23T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Citius Oncology reports FY 2025 net loss of $24.8M; launches LYMPHIR in U.S.","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $24.8M ($0.34 per share) vs $21.1M ($0.31) in FY 2024, driven by pre-commercial investment.","Cash and equivalents $3.9M as of Sep 30, 2025; raised $36M in three financings post- and intra-year.","LYMPHIR launched in U.S. Dec 2025; distribution agreements with top three wholesalers secured.","International access via Named Patient Programs in 19 markets; collaboration with Verix for AI-driven commercial targeting.","R&D expense $6.4M (up from $4.9M); G&A $8.8M ($8.1M prior); stock-based comp $8.3M ($7.5M)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":79963831.34210822,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":126516,"accession_number":"0001213900-25-120197","cik":1851484,"company_name":"CITIUS ONCOLOGY, INC.","ticker":"CTOR","form_type":"8-K","filed_at":"2025-12-10T23:59:59+00:00","items":["1.01","3.02","8.01","9.01"],"status":"ready","headline":"Citius Oncology raises $18M in registered direct & private placement; funds LYMPHIR launch","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds ~$18M from sale of 1,284,404 shares at $1.09 + 15,229,358 pre-funded warrants at $1.0899 per unit.","Net proceeds ~$15.2M after fees; H.C. Wainwright acted as placement agent (7% fee).","Concurrent private placement includes warrants exercisable at $1.09 upon stockholder approval, 5-year term.","Existing warrants for 11,961,040 shares amended to $1.09 exercise price and exercisable after stockholder approval.","Citius Pharma promissory note maturity amended to require $50M of gross proceeds raised before maturity."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":79963831.34210822,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":126515,"accession_number":"0001213900-25-116764","cik":1851484,"company_name":"CITIUS ONCOLOGY, INC.","ticker":"CTOR","form_type":"8-K","filed_at":"2025-12-01T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Citius Oncology launches LYMPHIR, first commercial product, for CTCL","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["LYMPHIR (denileukin diftitox-cxdl) now available nationwide via specialty distributors.","Phase 3 pivotal study: 36.2% ORR, median time to response 1.4 months, no cumulative toxicity.","Entering U.S. market estimated >$400M; permanent J-code J9161 and NCCN Category 2A inclusion.","Ex-U.S. distribution pact with Integris Pharma for 12 Southern European/Balkan markets.","Company holds exclusive rights to all markets except India, Japan, and parts of Asia."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":79963831.34210822,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":126514,"accession_number":"0001213900-25-102625","cik":1851484,"company_name":"CITIUS ONCOLOGY, INC.","ticker":"CTOR","form_type":"8-K","filed_at":"2025-10-27T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Citius Oncology shareholders approve doubling of stock incentive plan shares to 30M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["At Oct 27 annual meeting, shareholders elected Class I directors Myron Holubiak and Joel Mayersohn for three-year terms.","Shareholders approved amendment to 2024 Omnibus Stock Incentive Plan, increasing authorized shares from 15M to 30M.","Ratification of Wolf & Company as independent auditor for fiscal year ending Sep 30, 2025 passed with 77.7M votes in favor.","Plan amendment doubles share pool for equity awards; approved by board Sep 19, 2025, now effective."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":79963831.34210822,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":126513,"accession_number":"0001213900-25-101737","cik":1851484,"company_name":"CITIUS ONCOLOGY, INC.","ticker":"CTOR","form_type":"8-K","filed_at":"2025-10-23T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Citius Oncology corporate presentation confirms LYMPHIR launch in Q4 2025; $400M+ market","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["LYMPHIR (denileukin diftitox) FDA-approved Aug 2024 for relapsed/refractory CTCL; first new systemic therapy since 2018.","Commercial launch readiness nearing completion; ~$90M invested to date, 12-18 month inventory manufactured.","New permanent J-code (J9161) secured; NCCN guidelines inclusion; sales force hiring underway.","Clinical data: 36% ORR (9% CR, 27% PR), median 1.4 months to response, 6.5 months median duration of response.","Ongoing combo studies: with KEYTRUDA (27% ORR in solid tumors) and CAR-T; prelim data expected Q4 2025/Q1 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":79963831.34210822,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":143266,"accession_number":"0001213900-25-089615","cik":1851484,"company_name":"CITIUS ONCOLOGY, INC.","ticker":"CTOR","form_type":"8-K","filed_at":"2025-09-19T23:59:59+00:00","items":["3.02","5.02","9.01"],"status":"ready","headline":"Citius Oncology doubles share reserve to 30M under 2024 equity plan; issues 360K warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board approved amendment to 2024 Omnibus Stock Incentive Plan, increasing authorized shares from 15M to 30M.","Issued warrants to purchase 360K shares of common stock at $2.1875, exercisable March 10, 2026, expiring 2031.","Warrants issued in private placement under Section 4(a)(2) to a financial advisor.","No other changes were made to the 2024 Plan besides the share increase."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":79963831.34210822,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":143265,"accession_number":"0001213900-25-086568","cik":1851484,"company_name":"CITIUS ONCOLOGY, INC.","ticker":"CTOR","form_type":"8-K","filed_at":"2025-09-10T23:59:59+00:00","items":["1.01","3.02","8.01","9.01"],"status":"ready","headline":"Citius Oncology raises $9.0M in registered direct offering and warrant private placement","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Sold 5,142,858 shares and warrants for 5,142,858 shares at $1.75/unit for gross proceeds of $9.0M.","Net proceeds approximately $7.48M after placement agent fees and expenses.","Warrants exercisable at $1.84/share, starting six months post-issuance, expiring in 5.5 years.","Maxim Group acted as placement agent, receiving 7% cash fee and warrants for 205,714 shares at $1.92.","Promissory note with Citius Pharma amended: maturity now contingent on raising at least $30M aggregate capital."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":79963831.34210822,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":143264,"accession_number":"0001213900-25-078018","cik":1851484,"company_name":"CITIUS ONCOLOGY, INC.","ticker":"CTOR","form_type":"8-K","filed_at":"2025-08-18T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Citius Oncology files prospectus supplement to update S-1 registration statement following 10-Q filing","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Prospectus supplement filed August 18, 2025; original S-1 effective July 15, 2025.","Public offering of common stock and warrants closed July 17, 2025.","Supplement needed because Citius Oncology not yet eligible to incorporate 10-Q by reference into S-1."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.05,"calibrated_materiality_score":0.05,"market_cap_usd":79963831.34210822,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":143263,"accession_number":"0001213900-25-075014","cik":1851484,"company_name":"CITIUS ONCOLOGY, INC.","ticker":"CTOR","form_type":"8-K","filed_at":"2025-08-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Citius Oncology reports Q3 net loss $5.4M; LYMPHIR launch on track for Q4 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $5.4M ($0.08/share) for fiscal Q3 ended June 30, 2025, vs $4.8M ($0.07) a year ago.","LYMPHIR commercial launch planned for Q4 2025; launch supplies and distribution agreements in place.","Raised $12.5M gross from parent equity offerings in Q3; Citius Oncology raised additional $9M in July 2025.","On July 17, 2025, closed public offering with net proceeds of approximately $7.4M.","Cash and cash equivalents were $112 as of June 30, 2025, subsequently improved by July financings."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.28,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":79963831.34210822,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":143262,"accession_number":"0001213900-25-065334","cik":1851484,"company_name":"CITIUS ONCOLOGY, INC.","ticker":"CTOR","form_type":"8-K","filed_at":"2025-07-18T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Citius Oncology closes $9.0M public offering of 6.82M shares & warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Priced 6,818,182 units at $1.32 each, each consisting of 1 share + 1 warrant for 1 common share.","Gross proceeds ~$9.0M; net proceeds ~$7.44M after placement agent fees and expenses.","Warrants exercisable at $1.32/share, immediately exercisable, expire 5 years from issuance.","Proceeds to support LYMPHIR commercialization, milestone/royalty payments, and working capital.","Placement agent Maxim Group LLC; 45-day lock-up on new share issuance after closing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":79963831.34210822,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":161396,"accession_number":"0001213900-25-059084","cik":1851484,"company_name":"CITIUS ONCOLOGY, INC.","ticker":"CTOR","form_type":"8-K","filed_at":"2025-06-27T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Citius Oncology regains Nasdaq minimum bid price compliance","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq compliance notice on June 26, 2025, for Listing Rule 5550(a)(2).","Common stock closing bid price was $1.00+ for 12 consecutive trading days (June 6–24, 2025).","Nasdaq considers the bid price deficiency matter closed.","Company avoids delisting; its common stock remains listed on Nasdaq Capital Market.","Ticker CTOR; compliance regained after previous bid price shortfall."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":79963831.34210822,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":161395,"accession_number":"0001213900-25-055182","cik":1851484,"company_name":"CITIUS ONCOLOGY, INC.","ticker":"CTOR","form_type":"8-K","filed_at":"2025-06-17T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Citius Oncology nearing commercial launch of LYMPHIR for CTCL in H2 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Commercial-scale manufacturing completed; inventory sufficient for 12-18 months post-launch with 60-month shelf life.","70 institutional oncology centers already registered via the LYMPHIR website.","LYMPHIR included in NCCN guidelines; assigned permanent J-code for reimbursement.","Parent Citius Pharma's recent capital raise supports final launch preparations.","Strategic partnership discussions underway with financial advisor to expand market reach."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":79963831.34210822,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":161394,"accession_number":"0001213900-25-043363","cik":1851484,"company_name":"CITIUS ONCOLOGY, INC.","ticker":"CTOR","form_type":"8-K","filed_at":"2025-05-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Citius Oncology Q2 net loss widens to $7.7M; cash only $112, needs funding beyond May 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $7.7M ($0.11 per share) vs $4.8M loss a year ago; R&D and G&A expenses increased due to launch activities.","Cash and equivalents at March 31, 2025 totaled just $112; company requires additional capital to sustain operations beyond May 2025.","Retained Jefferies LLC as exclusive financial advisor to evaluate strategic alternatives aimed at maximizing stockholder value.","Advancing commercial launch of LYMPHIR (cutaneous T-cell lymphoma) after FDA approval; discussions with partners ongoing."],"consensus_eps_estimate":-0.153,"consensus_eps_actual":-0.2,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q2","consensus_source":"xbrl+finnhub","sentiment":"negative","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":79963831.34210822,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":161393,"accession_number":"0001213900-25-035575","cik":1851484,"company_name":"CITIUS ONCOLOGY, INC.","ticker":"CTOR","form_type":"8-K","filed_at":"2025-04-25T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Citius Oncology receives Nasdaq deficiency notice for bid price below $1.00","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Nasdaq notified Citius Oncology that its common stock bid price closed below $1.00 for 30 consecutive business days.","Company has 180 calendar days (until October 20, 2025) to regain compliance with the Bid Price Rule.","If stock closes at $1.00 or more for ten consecutive business days, Nasdaq will confirm compliance.","If not compliant by October 20, 2025, the Company may be eligible for an additional 180-day period, subject to conditions.","Company is evaluating options, including a potential reverse stock split, to regain compliance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":79963831.34210822,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":161392,"accession_number":"0001213900-25-028621","cik":1851484,"company_name":"CITIUS ONCOLOGY, INC.","ticker":"CTOR","form_type":"8-K","filed_at":"2025-04-03T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Citius Oncology restructures $14.1M payment obligation to Eisai for LYMPHIR milestone and development costs","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Total owed: $5.9M milestone payment plus $8.23M in development and inventory costs.","Payment schedule: $2.535M due July 15, 2025; then four monthly $2.35M payments; final $2.198M due Dec 15, 2025.","Interest at 2% per annum accrues from original due dates until actual payment.","Parties release each other from claims related to past non-payment; License Agreement otherwise unchanged."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":79963831.34210822,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":179569,"accession_number":"0001213900-25-014351","cik":1851484,"company_name":"CITIUS ONCOLOGY, INC.","ticker":"CTOR","form_type":"8-K","filed_at":"2025-02-14T23:59:59+00:00","items":["8.01","2.02","9.01"],"status":"ready","headline":"Citius Oncology reports wider Q1 net loss of $6.7M; engaged Jefferies for strategic alternatives","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $6.7M ($0.09/share) vs $4.7M ($0.07) in Q1 fiscal 2024.","G&A expenses rose to $3.3M from $1.5M on pre-commercial launch costs for LYMPHIR.","Engaged Jefferies as exclusive financial advisor to evaluate strategic alternatives; active discussions underway.","Received permanent J-code J9161 for LYMPHIR effective April 1, 2025; launch on track for H1 2025.","R&D expenses were $1.3M, up from $1.2M, supporting two investigator-initiated trials."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.09,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":79963831.34210822,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":179568,"accession_number":"0001213900-25-010748","cik":1851484,"company_name":"CITIUS ONCOLOGY, INC.","ticker":"CTOR","form_type":"8-K","filed_at":"2025-02-06T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"LYMPHIR assigned permanent J-code J9161 by CMS, effective April 1, 2025","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["LYMPHIR (denileukin diftitox-cxdl) received permanent HCPCS J-code J9161 for IV use, 1 microgram.","J-code effective April 1, 2025, for claims submission by healthcare providers.","Code facilitates billing and reimbursement for commercial and government insurance (VA, DoD, Medicare).","Chairman Leonard Mazur states milestone supports patient access and coding clarity."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":79963831.34210822,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":179567,"accession_number":"0001213900-25-001407","cik":1851484,"company_name":"CITIUS ONCOLOGY, INC.","ticker":"CTOR","form_type":"8-K","filed_at":"2025-01-07T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Citius Oncology provides LYMPHIR launch update; commercialization planned for H1 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["LYMPHIR (immunotherapy for CTCL) approved Aug 2024; launch targeted for first half of 2025.","First-year launch supply produced under commercial supply agreements with CMOs.","J-code application submitted under HCPCS; NCCN guidelines inclusion secured.","Patient assistance program and specialized field sales team under development.","Exploring international licensing partnerships and expanded indications for LYMPHIR."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":79963831.34210822,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":179566,"accession_number":"0001213900-25-000953","cik":1851484,"company_name":"CITIUS ONCOLOGY, INC.","ticker":"CTOR","form_type":"8-K","filed_at":"2025-01-06T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Citius Oncology retains Jefferies to explore strategic alternatives including sale or licensing","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Jefferies LLC appointed as exclusive financial advisor to assist in evaluating strategic alternatives.","Alternatives under consideration include partnerships, joint ventures, mergers, acquisitions, and licensing.","Company is preparing to launch LYMPHIR, FDA-approved for relapsed/refractory Stage I-III cutaneous T-cell lymphoma.","No timeline set; no assurance that a transaction will result from the review process."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":79963831.34210822,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":196296,"accession_number":"0001213900-24-113159","cik":1851484,"company_name":"CITIUS ONCOLOGY, INC.","ticker":"CTOR","form_type":"8-K","filed_at":"2024-12-27T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Citius Oncology full-year net loss widens to $21.1M; FDA-approved LYMPHIR launch on track for H1 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $21.1M ($0.31/sh) vs $12.7M ($0.19/sh) for FY ended Sep 30, 2024.","FDA approved LYMPHIR for relapsed/refractory CTCL; commercial launch planned H1 2025.","Pre-commercial activities: J-code application, NCCN inclusion, CSO recruitment, inventory built.","R&D $4.9M, G&A $8.1M, stock-based comp $7.5M vs $4.2M, $5.9M, $2.0M YoY.","Phase I combo with pembrolizumab showed 27% ORR, 33% CBR, median PFS 57 weeks in gynecological tumors."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":79963831.34210822,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":196295,"accession_number":"0001213900-24-096269","cik":1851484,"company_name":"CITIUS ONCOLOGY, INC.","ticker":"CTOR","form_type":"8-K","filed_at":"2024-11-12T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Citius Oncology reports 27% ORR, 33% CBR in Phase I trial of LYMPHIR + pembrolizumab for recurrent solid tumors","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["27% objective response rate (4/15 evaluable) and 33% clinical benefit rate (5/15) in heavily pre-treated gynecologic tumors.","Median progression-free survival of 57 weeks (range 30-96 weeks) for patients achieving clinical benefit.","Combination was well-tolerated with no documented ≥Grade 3 immune-related adverse events; one dose-limiting toxicity (capillary leak) at 12 mcg/kg.","Two of four partial responders had failed prior anti-PD-1 therapy, suggesting potential to overcome checkpoint resistance.","Trial nearing completion with three additional patients to enroll; data presented at SITC 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":79963831.34210822,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":212585,"accession_number":"0001213900-24-078287","cik":1851484,"company_name":"CITIUS ONCOLOGY, INC.","ticker":"CTOR","form_type":"8-K","filed_at":"2024-09-13T23:59:59+00:00","items":["1.01"],"status":"ready","headline":"Citius Oncology secures partial deferral of milestone payment to Dr. Reddy's without penalty","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Milestone payment triggered by FDA approval of LYMPHIR was due Sept 9, 2024; partial deferral granted without penalty.","All other terms and conditions of the Asset Purchase Agreement remain in full force and effect.","Further discussions with Dr. Reddy's pending; partial deferral avoids immediate cash outflow."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":79963831.34210822,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":212584,"accession_number":"0001213900-24-076111","cik":1851484,"company_name":"CITIUS ONCOLOGY, INC.","ticker":"CTOR","form_type":"8-K","filed_at":"2024-09-05T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Citius Oncology's LYMPHIR added to NCCN Guidelines (Category 2A) for CTCL","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["LYMPHIR (denileukin diftitox-cxdl) included in NCCN Guidelines for relapsed/refractory Cutaneous T-cell Lymphoma as Category 2A recommendation.","FDA-approved therapy targets IL-2 receptor on malignant T-cells; Phase 3 Study 302 supported approval.","CEO Mazur states inclusion may aid adoption and ease reimbursement, especially for CMS coverage.","NCCN Guidelines are widely used for clinical decision-making and payer reimbursement in the U.S."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":79963831.34210822,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":212582,"accession_number":"0001213900-24-072598","cik":1851484,"company_name":"CITIUS ONCOLOGY, INC.","ticker":"CTOR","form_type":"8-K/A","filed_at":"2024-08-26T23:59:59+00:00","items":["2.01","9.01"],"status":"ready","headline":"SpinCo reports $14.3M net loss for nine months; going concern uncertainty raised","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Net loss of $14.3M for nine months ended June 30, 2024 (vs $7.5M prior year); no revenue.","Working capital deficit of $21.4M; cash balance $0 at June 30, 2024.","Due to related party (Citius Pharma) $30.9M, up from $19.5M at Sept 30, 2023.","Company expresses substantial doubt about ability to continue as going concern within one year.","Stock-based compensation expense $5.8M for the nine months; $40M in-process R&D asset for LYMPHIR."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":79963831.34210822,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":212583,"accession_number":"0001213900-24-070335","cik":1851484,"company_name":"CITIUS ONCOLOGY, INC.","ticker":"CTOR","form_type":"8-K","filed_at":"2024-08-16T23:59:59+00:00","items":["1.01","2.01","5.06","9.01","5.02","3.02","3.03","4.01","5.01","5.03"],"status":"ready","headline":"Citius Oncology completes de-SPAC business combination; CTOR begins trading","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Citius Pharma received 65.6M shares (~92.6% ownership); 4.3M SPAC shares redeemed for ~$49.3M ($11.47 each).","Company Common Stock began trading on Nasdaq Capital Market as 'CTOR' on August 13, 2024.","Leonard Mazur appointed CEO & Chair; Jaime Bartushak CFO; Myron Holubiak Secretary/Treasurer; Myron Czuczman CMO.","Citius Pharma contributed $10M capital; waivers include LYMPHIR trademark transfer within 60 days post-closing.","71.3M shares outstanding post-closing; board of 8 directors with staggered terms; controlled company under Nasdaq rules."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":79963831.34210822,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":212587,"accession_number":"0001493152-24-030145","cik":1851484,"company_name":"CITIUS ONCOLOGY, INC.","ticker":"CTOR","form_type":"8-K","filed_at":"2024-08-05T23:59:59+00:00","items":["5.02","5.07","8.01","9.01"],"status":"ready","headline":"TenX Keane shareholders approve business combination with Citius Oncology; redemptions total $49.3M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All eight proposals approved, including business combination, domestication to Delaware, name change to Citius Oncology, and 15M-share stock incentive plan.","4,297,828 shares redeemed at ~$11.46 per share, aggregating $49,265,965 from trust account.","Eight directors elected to staggered terms: Myron Holubiak, Joel Mayersohn, Dr. Eugene Holuka, Robert Smith, Carol Webb, Suren Dutia, Leonard Mazur, Dennis McGrath.","Business combination involves Citius Oncology (spin-off from Citius Pharma) merging into TenX; closing conditions still pending.","Incentive plan authorizes options, SARs, restricted stock, RSUs, and cash awards for employees, directors, and consultants."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":79963831.34210822,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":212586,"accession_number":"0001493152-24-028500","cik":1851484,"company_name":"CITIUS ONCOLOGY, INC.","ticker":"CTOR","form_type":"8-K","filed_at":"2024-07-19T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"TenX Keane Acquisition extends business combination deadline to August 18, 2024 via $66,667 note from Citius Pharma","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Citius Pharma deposited $66,667 into trust to extend deadline from July 18 to August 18, 2024; fourth monthly extension.","Prior extensions occurred on April 26, May 17, and June 17, 2024; Company can extend up to November 18, 2024.","Promissory note is unsecured, bears no interest, and is repayable only upon closing if trust balance >= $2M.","Extension funded under Merger Agreement; Note is evidenced by Exhibit 10.4 to this 8-K."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":79963831.34210822,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":231588,"accession_number":"0001493152-24-024236","cik":1851484,"company_name":"CITIUS ONCOLOGY, INC.","ticker":"CTOR","form_type":"8-K","filed_at":"2024-06-18T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"TenX Keane extends SPAC deadline to July 18 with $66,667 Citius Pharma deposit","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Citius Pharma deposited $66,667 into TenX Keane trust account to extend business combination timeline from June 18 to July 18, 2024.","TenX issued $66,667 unsecured promissory note to Citius Pharma, no interest, repayable upon business combination close.","This is the third of up to seven allowed monthly extensions; prior deposits on April 26 and May 17, 2024.","Extension supports pending Merger Agreement to acquire Citius Oncology; repayment condition tied to trust account balance ≥$2M."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":79963831.34210822,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":231587,"accession_number":"0001493152-24-022977","cik":1851484,"company_name":"CITIUS ONCOLOGY, INC.","ticker":"CTOR","form_type":"8-K","filed_at":"2024-06-06T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"TenX Keane pays additional $268,645 to redeeming shareholders after redemption price miscalculation","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Holders of 2,287,923 shares redeemed at $10.90/share on Jan 17, 2024, for ~$24.9M.","Correct redemption price should have been $11.02/share, based on Jan 12, 2024 calculation.","On May 31, 2024, company paid $268,645 aggregate top-up to cover the $0.12/share shortfall.","Total redemption amount adjusted to ~$25.2M using corrected price of $11.02 per share."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":79963831.34210822,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":231586,"accession_number":"0001493152-24-020866","cik":1851484,"company_name":"CITIUS ONCOLOGY, INC.","ticker":"CTOR","form_type":"8-K","filed_at":"2024-05-21T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"TenX Keane Acquisition extends deadline to June 18, 2024 via $66,667 deposit from Citius Pharma","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Citius Pharma deposited $66,667 on May 17, 2024 to extend business combination deadline from May 18 to June 18, 2024.","The deposit is the second of up to seven monthly extensions allowed under the charter, originally expiring April 18, 2024.","The extension is funded via an unsecured, non-interest-bearing promissory note repayable upon consummation of the business combination.","Repayment of the note is conditioned on the trust account balance equaling or exceeding $2.0 million at closing of the merger with Citius Oncology.","The merger agreement with Citius Pharmaceuticals and Citius Oncology was dated October 23, 2023, and remains pending."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":79963831.34210822,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":231585,"accession_number":"0001493152-24-017024","cik":1851484,"company_name":"CITIUS ONCOLOGY, INC.","ticker":"CTOR","form_type":"8-K","filed_at":"2024-04-29T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"TenX Keane Acquisition extends business combination deadline to May 18, 2024 with $66,667 deposit","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Citius Pharma deposited $66,667 into trust to extend deadline from April 18 to May 18, 2024.","Extension funded by unsecured promissory note issued to Citius Pharma; note bears no interest, repayable at close.","Sponsor may extend up to seven additional months through Nov 18, 2024 with similar monthly deposits.","Merger agreement with Citius Oncology dated October 23, 2023 remains pending."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":79963831.34210822,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}